Biora Therapeutics, Inc.

Biora Therapeutics, Inc. priced its initial public offering on Jun 22, 2020 at $15.00 per share, within its $14.00–$16.00 range, raising $100M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $677.5M. Piper Sandler was lead-left underwriter, joined by Wells Fargo, Baird and Raymond James and others. Gibson Dunn advised the company and Latham & Watkins advised the underwriters.

Biora Therapeutics, Inc. is a biotechnology company that develops and sells in vitro molecular tests for decisions in areas such as family planning, pregnancy and disease diagnosis. It applies a multi-omics approach to those tests and to investigational ingestible devices and drug/device combinations for localized treatment.

Status

IPO

Exchange

Nasdaq Global Market

Priced

Jun 22, 2020

IPO price

$15.00

Price range

$14.00–$16.00

Raised

$100M

Market cap at IPO price

$677.5M

First filed

May 27, 2020

Underwriters

Piper Sandler, Wells Fargo, Baird, Raymond James and BTIG

Company counsel

Gibson Dunn

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.